OBJECTIVE: Glucocorticoids are recommended for short-term use in rheumatoid arthritis (RA), but many patients continue receiving long-term therapy. We evaluated the variability in glucocorticoid prescribing across rheumatologists to inform interventions to limit long-term glucocorticoid use to the lowest dose necessary. METHODS: Two cohorts were created using Medicare data from 2006 to 2015. Using cohort 1 (RA patients receiving disease-modifying antirheumatic drugs [DMARDs]), we calculated each rheumatologist's "provider preference" for glucocorticoids (frequency of use compared to other providers), using the ratio of observed to expected number of patients receiving glucocorticoids to account for case mix. In cohort 2 (RA patients receiving stable DMARD therapy), we evaluated whether provider preference for glucocorticoids could independently predict use of ≥5 mg/day of glucocorticoids 6-9 months after initiation of DMARD therapy. RESULTS: Using cohort 1 (1,272,644 yearly observations; 385,597 patients), we calculated provider preference among 6,875 rheumatologists (28,936 yearly observations). Provider preference was highly variable, with physicians at the lowest and upper quartiles prescribing glucocorticoids 33% less often to 31% more often (25th and 75th percentiles, respectively) than expected. In cohort 2 (155,539 patients receiving stable DMARD therapy), provider preference was strongly associated with glucocorticoid use ≥5 mg/day at 6-9 months, with a predicted probability of use of 22% (95% confidence interval [95% CI] 21.7-22.7) versus 11% (95% CI 10.2-10.9) for a patient seeing a provider in the highest versus lowest quintile of preference. CONCLUSION: Glucocorticoid prescribing for RA varies greatly among rheumatologists, and provider preference is one of the strongest predictors of a patient's long-term glucocorticoid use. These findings raise quality of care concerns and highlight the need for stronger evidence to guide RA treatment.
OBJECTIVE: Glucocorticoids are recommended for short-term use in rheumatoid arthritis (RA), but many patients continue receiving long-term therapy. We evaluated the variability in glucocorticoid prescribing across rheumatologists to inform interventions to limit long-term glucocorticoid use to the lowest dose necessary. METHODS: Two cohorts were created using Medicare data from 2006 to 2015. Using cohort 1 (RA patients receiving disease-modifying antirheumatic drugs [DMARDs]), we calculated each rheumatologist's "provider preference" for glucocorticoids (frequency of use compared to other providers), using the ratio of observed to expected number of patients receiving glucocorticoids to account for case mix. In cohort 2 (RA patients receiving stable DMARD therapy), we evaluated whether provider preference for glucocorticoids could independently predict use of ≥5 mg/day of glucocorticoids 6-9 months after initiation of DMARD therapy. RESULTS: Using cohort 1 (1,272,644 yearly observations; 385,597 patients), we calculated provider preference among 6,875 rheumatologists (28,936 yearly observations). Provider preference was highly variable, with physicians at the lowest and upper quartiles prescribing glucocorticoids 33% less often to 31% more often (25th and 75th percentiles, respectively) than expected. In cohort 2 (155,539 patients receiving stable DMARD therapy), provider preference was strongly associated with glucocorticoid use ≥5 mg/day at 6-9 months, with a predicted probability of use of 22% (95% confidence interval [95% CI] 21.7-22.7) versus 11% (95% CI 10.2-10.9) for a patient seeing a provider in the highest versus lowest quintile of preference. CONCLUSION: Glucocorticoid prescribing for RA varies greatly among rheumatologists, and provider preference is one of the strongest predictors of a patient's long-term glucocorticoid use. These findings raise quality of care concerns and highlight the need for stronger evidence to guide RA treatment.
Authors: Björn Svensson; Annelies Boonen; Kristina Albertsson; Désirée van der Heijde; Catharina Keller; Ingiäld Hafström Journal: Arthritis Rheum Date: 2005-11
Authors: Carlos G Grijalva; Lang Chen; Elizabeth Delzell; John W Baddley; Timothy Beukelman; Kevin L Winthrop; Marie R Griffin; Lisa J Herrinton; Liyan Liu; Rita Ouellet-Hellstrom; Nivedita M Patkar; Daniel H Solomon; James D Lewis; Fenglong Xie; Kenneth G Saag; Jeffrey R Curtis Journal: JAMA Date: 2011-11-06 Impact factor: 56.272
Authors: Marije F Bakker; Johannes W G Jacobs; Paco M J Welsing; Suzanne M M Verstappen; Janneke Tekstra; Evelien Ton; Monique A W Geurts; Jacobine H van der Werf; Grietje A van Albada-Kuipers; Zalima N Jahangier-de Veen; Maaike J van der Veen; Catharina M Verhoef; Floris P J G Lafeber; Johannes W J Bijlsma Journal: Ann Intern Med Date: 2012-03-06 Impact factor: 25.391
Authors: Jasvinder A Singh; Kenneth G Saag; S Louis Bridges; Elie A Akl; Raveendhara R Bannuru; Matthew C Sullivan; Elizaveta Vaysbrot; Christine McNaughton; Mikala Osani; Robert H Shmerling; Jeffrey R Curtis; Daniel E Furst; Deborah Parks; Arthur Kavanaugh; James O'Dell; Charles King; Amye Leong; Eric L Matteson; John T Schousboe; Barbara Drevlow; Seth Ginsberg; James Grober; E William St Clair; Elizabeth Tindall; Amy S Miller; Timothy McAlindon Journal: Arthritis Rheumatol Date: 2015-11-06 Impact factor: 10.995
Authors: Katinka Albrecht; Klaus Krüger; Jürgen Wollenhaupt; Rieke Alten; Marina Backhaus; Christoph Baerwald; Wolfgang Bolten; Jürgen Braun; Harald Burkhardt; Gerd R Burmester; Markus Gaubitz; Angela Gause; Erika Gromnica-Ihle; Herbert Kellner; Jens Kuipers; Andreas Krause; Hans-Martin Lorenz; Bernhard Manger; Hubert Nüßlein; Hans-Georg Pott; Andrea Rubbert-Roth; Matthias Schneider; Christof Specker; Hendrik Schulze-Koops; Hans-Peter Tony; Siegfried Wassenberg; Ulf Müller-Ladner Journal: Rheumatol Int Date: 2013-08-14 Impact factor: 2.631
Authors: Cindy Strehl; Johannes W J Bijlsma; Maarten de Wit; Maarten Boers; Nele Caeyers; Maurizio Cutolo; Bhaskar Dasgupta; William G Dixon; Rinie Geenen; Tom W J Huizinga; Alison Kent; Annette Ladefoged de Thurah; Joachim Listing; Xavier Mariette; David W Ray; Hans U Scherer; Raphaèle Seror; Cornelia M Spies; Simon Tarp; Dieter Wiek; Kevin L Winthrop; Frank Buttgereit Journal: Ann Rheum Dis Date: 2016-03-01 Impact factor: 19.103
Authors: Rachel J Black; Rebecca M Joseph; Benjamin Brown; Mohammad Movahedi; Mark Lunt; William G Dixon Journal: Arthritis Res Ther Date: 2015-12-24 Impact factor: 5.156
Authors: Michael D George; Jesse Y Hsu; Sean Hennessy; Lang Chen; Fenglong Xie; Jeffrey R Curtis; Joshua F Baker Journal: Epidemiology Date: 2022-01-01 Impact factor: 4.822
Authors: Beth I Wallace; Meriah N Moore; Andrew C Heisler; Lutfiyya N Muhammad; Jing Song; Daniel J Clauw; Clifton O Bingham; Marcy B Bolster; Wendy Marder; Tuhina Neogi; Alyssa Wohlfahrt; Dorothy D Dunlop; Yvonne C Lee Journal: Rheumatology (Oxford) Date: 2022-04-11 Impact factor: 7.046